Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
Bouzas C, Pastor R, Garcia S, Monserrat-Mesquida M, Martínez-González MÁ, Salas-Salvadó J, Corella D, Goday A, Martínez JA, Alonso-Gómez ÁM, Fernández-Barceló O, Vioque J, Romaguera D, Lopez-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem L, Riquelme-Gallego B, Martín-Sánchez V, Pintó X, Delgado-Rodriguez M, Matía P, Vidal J, Cardenas-Salas JJ, Daimiel L, Ros E, Toledo E, Manzanares JM, Gonzalez-Monge I, Muñoz MÁ, Martinez-Urbistondo D, Tojal-Sierra L, Muñoz-Bravo C, Miralles-Gisbert S, Martin M, García-Ríos A, Castro-Barquero S, Fernández-García JC, Santos-Lozano JM, Basterra-Gortari FJ, Gutiérrez-Carrasquilla L, Guillem-Saiz P, Satorres A, Abete I, Sorto-Sanchez C, Díez-Espino J, Babio N, Fitó M, Tur JA.
Bouzas C, et al.
Biomed Pharmacother. 2023 May;161:114561. doi: 10.1016/j.biopha.2023.114561. Epub 2023 Mar 17.
Biomed Pharmacother. 2023.
PMID: 36934556
Free article.
GLP-1RA and DPP-4I participants registered the lowest decrease in BMI ( untreated: -0.8( 1.6) kg/m(2); metformin: - 0.8( 1.5) kg/m(2); DPP-4I: - 0.6( 1.3) kg/m(2); GLP-1RA: - 0.5( 1.2) kg/m(2). and their waist circumference ( untreated: -2.8( 5.2) cm; …
GLP-1RA and DPP-4I participants registered the lowest decrease in BMI ( untreated: -0.8( 1.6) kg/m(2); metformin: - 0.8( 1.5) kg/m …